primary insomnia การใช้

• Primary insomnia is a sleep disorder not attributable to a medical, psychiatric, or environmental cause.
• Primary insomnia is a disorder in which a patient has difficulty initiating and maintaining sleep.
• Rebound insomnia is insomnia that occurs following discontinuation of sedative substances taken to relieve primary insomnia.
• There are three main types of primary insomnia.
• Others, such as chronic and primary insomnia, may be more amenable to behavioral interventions, with more durable results.
• Panic disorder leads to 7 million years lost, obsessive-compulsive disorder 5.1, primary insomnia 3.6, and post-traumatic stress disorder 3.5 million DALYs.
• Dyssomnia is a class of sleep disorders which includes Primary insomnia, primary hypersomnia, narcolepsy, breathing-related sleep disorders, circadian rhythm sleep discorer, and other conditions.
• However, since many doctors are unfamiliar with the condition, it often goes untreated or is treated inappropriately; DSPD is often misdiagnosed as primary insomnia or as a psychiatric condition.
• Impaired memory consolidation has been effected in individuals with primary insomnia who thus do not perform as well as normal patients in memory tasks following a period of sleep.
• The condition, known as persistent primary insomnia, is believed to affect about 14 million people in this country, most over 40, and it is associated with a variety of health problems.
• Edinger's report, which is detailed in the current edition of the Journal of the American Medical Association, is a study of patients with persistent primary insomnia, a condition that affects some 5 percent of Americans.
• Melatonin in the form of prolonged release ( trade name Circadin ?) was approved in 2007 in Europe ( EU ) for use as a short-term treatment, in patients 55 years and older, for primary insomnia.
• On 16 August 2013, information was released on the Facebook page by IAMX manager Reza Davoudi, that IAMX would be rescheduling the 2013 fall'Screams'tour for 2014 after Chris had been diagnosed with chronic primary insomnia and was seeking treatment.
• Melatonin in the form of prolonged release ( trade name Circadin ?) was approved in 2007 in Europe ( EU ) for use as a short-term treatment, in patients 55 years or older, for primary insomnia ( poor quality of sleep ).
• In June 2007, the European Medicines Agency approved EU . The drug is a prolonged-release melatonin, 2 mg, for patients aged 55 and older, as monotherapy for the short-term treatment ( up to 13 weeks ) of primary insomnia characterized by poor quality of sleep.